Clinical Study

Randomized Phase II Study Of Irinotecan And Cetuximab With Or Without Vemurafenib In Braf Mutant Metastatic Colorectal Cancer.

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare any good/bad effects of using vemurafenib along with the usual chemotherapy, cetuximab and irinotecan, to using the usual chemotherapy approach alone. This study will allow researchers to know whether this different approach is better, the same or worse than t

Criteria:

To Be Eligible For This Study, Patients Must Have Colorectal Cancer Which Has Grown Or Has Recurred.

Keywords:

Gastrointestinal Can, S1406, Cancer, Braf Mutant, Colorectal

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.